I discovered over the past week that there’s something special about a hurricane blackout in the middle of a pandemic. Your friends can offer you Wifi and an extension cord, but you have to stay outside on the porch, so that no viruses jump from host to host.

Aside from the weather, things still feel oddly stable in Connecticut. Since last month’s email, our daily cases have remained relatively low. Right now the seven-day average of daily new cases is 72. We’re averaging 1 death a day. That’s good compared to Florida, with 6440 daily new cases and 160 deaths a day. Continue reading “Friday’s Elk, August 12, 2020”

The New York Times, August 11, 2020

Link

When Vladimir Putin announced Tuesday that Russia had approved a coronavirus vaccine — with no evidence from large-scale clinical trials — vaccine experts were worried.

“I think it’s really scary. It’s really risky,” said Daniel Salmon, the director of the Institute for Vaccine Safety at Johns Hopkins University.

Dr. Salmon and other experts said that Russia is taking a dangerous step by jumping ahead of so-called Phase 3 trials, which can determine that the vaccine works better than a placebo and doesn’t cause harm to some people who get it.

Continue reading “‘This Is All Beyond Stupid.’ Experts Worry About Russia’s Rushed Vaccine”

The New York Times, August 4, 2020 (with Katie Thomas)

Link

Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary studies on Tuesday.

In one study, 56 volunteers produced a high level of antibodies against the virus without any dangerous side effects. In the other, researchers found that the vaccine strongly protected monkeys from coronavirus infections.

Although it’s not possible to directly compare the data from clinical trials of different coronavirus vaccines, John Moore, a virologist at Weill Cornell Medicine who was not involved in the studies, said the Novavax results were the most impressive he had seen so far.

Continue reading “Scientists Are Optimistic About New Vaccine Studies From Novavax”

The New York Times, July 30, 2020

Link

An experimental coronavirus vaccine developed by Johnson & Johnson protected monkeys from infection in a new study. It is the second vaccine candidate to show promising results in monkeys this week.

The company recently began a clinical trial in Europe and the United States to test its vaccine in people. It is one of more than 30 human trials for coronavirus vaccines underway across the world. But until these trials are complete — which will probably take several months — the monkey data offers the best clues to whether the vaccines will work.

Continue reading “Johnson & Johnson’s Coronavirus Vaccine Protects Monkeys, Study Finds”

The New York Times, July 17, 2020

Link

Each workday morning in March, Noe Mercado drove through the desolate streets of Boston to a tall glass building on Blackfan Circle, in the heart of the city’s biotech hub. Most residents had gone into hiding from the coronavirus, but Mr. Mercado had an essential job: searching for a vaccine against this new, devastating pathogen.

Parking in the underground lot, he put on a mask and rode the empty elevator to the tenth floor, joining a skeleton crew at the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. Day after day, Mr. Mercado sat at his lab bench, searching for signs of the virus in nasal swabs taken from dozens of monkeys.

Continue reading “Inside Johnson & Johnson’s Nonstop Hunt for a Coronavirus Vaccine”